207 related articles for article (PubMed ID: 25962442)
21. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
[TBL] [Abstract][Full Text] [Related]
22. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood.
van Beek RD; van den Heuvel-Eibrink MM; Laven JS; de Jong FH; Themmen AP; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Pieters R; de Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 2007 Oct; 92(10):3869-74. PubMed ID: 17726078
[TBL] [Abstract][Full Text] [Related]
23. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
24. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
25. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
26. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Fisher RI; Miller TP; Dana BW; Jones SE; Dahlberg S; Coltman CA
Semin Hematol; 1987 Apr; 24(2 Suppl 1):21-5. PubMed ID: 2438778
[TBL] [Abstract][Full Text] [Related]
27. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
[TBL] [Abstract][Full Text] [Related]
28. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
29. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
[TBL] [Abstract][Full Text] [Related]
30. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
Yuan ZY; Xu RH; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
[TBL] [Abstract][Full Text] [Related]
31. New treatment options have changed the survival of patients with follicular lymphoma.
Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
[TBL] [Abstract][Full Text] [Related]
32. Retrospective comparison between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma.
Gan H; Zhang F; Lin Y
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):397-9. PubMed ID: 12408775
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
34. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
[TBL] [Abstract][Full Text] [Related]
35. VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
Singer JM; Mijovic A; Pettingale KW; Nethersell A; Dobbs HJ; Samaratunga IR; Lakhani A; Mufti GJ
Clin Oncol (R Coll Radiol); 1995; 7(6):366-70. PubMed ID: 8590697
[TBL] [Abstract][Full Text] [Related]
36. Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group.
Bailey NP; Stuart NS; Bessell EM; Child JA; Norfolk D; Fletcher J; Grieve RJ; Simmons AV; Barnard DL; Jack A; Farish J; Dunn J; Woodroffe CM; Stack C; Cullen MH
Ann Oncol; 1998 Jun; 9(6):633-8. PubMed ID: 9681077
[TBL] [Abstract][Full Text] [Related]
37. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
[TBL] [Abstract][Full Text] [Related]
38. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
[TBL] [Abstract][Full Text] [Related]
39. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
Bessell EM; Burton A; Haynes AP; Glaholm J; Child JA; Cullen MH; Davies JM; Smith GM; Ellis IO; Jack A; Jones EL;
Ann Oncol; 2003 Feb; 14(2):258-67. PubMed ID: 12562653
[TBL] [Abstract][Full Text] [Related]
40. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]